3,873 Shares in IDEXX Laboratories, Inc. $IDXX Acquired by Prime Capital Investment Advisors LLC

Key Points

• Prime Capital Investment Advisors acquired 3,873 shares of IDEXX Laboratories during the third quarter, worth approximately $2.02 million. Institutional investors and hedge funds own 87.84% of the company.
• IDEXX reported quarterly EPS of $4.27, beating estimates of $3.94, while revenue rose 9.7% year over year to $1.22 billion. The company issued full-year 2026 EPS guidance of $14.69–$14.94.
• Analysts maintain a “Moderate Buy” consensus with an average price target of $744.09; Goldman Sachs initiated coverage with a Buy rating and a $740 target, while UBS and Citigroup kept neutral ratings with $670 targets.

Prime Capital Investment Advisors LLC purchased a new position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor purchased 3,873 shares of the company's stock, valued at approximately $2,022,000.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. J.Safra Asset Management Corp bought a new position in IDEXX Laboratories in the 2nd quarter valued at $25,000. SHP Wealth Management bought a new stake in shares of IDEXX Laboratories during the fourth quarter worth $26,000. Elevation Wealth Partners LLC grew its holdings in shares of IDEXX Laboratories by 188.2% during the second quarter. Elevation Wealth Partners LLC now owns 49 shares of the company's stock worth $26,000 after purchasing an additional 32 shares during the last quarter. Pension & Wealth Management Advisors Inc. acquired a new stake in shares of IDEXX Laboratories in the third quarter valued at $29,000. Finally, Arlington Trust Co LLC increased its stake in shares of IDEXX Laboratories by 46.3% in the second quarter. Arlington Trust Co LLC now owns 60 shares of the company's stock valued at $32,000 after buying an additional 19 shares in the last quarter. 87.84% of the stock is owned by institutional investors and hedge funds.

IDEXX Laboratories Price Performance

IDEXX Laboratories stock opened at $553.48 on Thursday. The business's 50-day simple moving average is $532.51 and its 200 day simple moving average is $551.60. The stock has a market cap of $43.60 billion, a price-to-earnings ratio of 38.92, a P/E/G ratio of 2.98 and a beta of 1.55. IDEXX Laboratories, Inc. has a 12-month low of $500.61 and a 12-month high of $769.98. The company has a quick ratio of 0.87, a current ratio of 1.17 and a debt-to-equity ratio of 0.19.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last released its earnings results on Tuesday, August 4th. The company reported $4.27 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $3.94 by $0.33. The company had revenue of $1.22 billion for the quarter, compared to the consensus estimate of $1.20 billion. IDEXX Laboratories had a net margin of 25.03% and a return on equity of 71.96%. The company's revenue was up 9.7% compared to the same quarter last year. During the same period in the prior year, the company posted $3.50 EPS. IDEXX Laboratories has set its FY 2026 guidance at 14.690-14.940 EPS. As a group, research analysts anticipate that IDEXX Laboratories, Inc. will post 14.81 earnings per share for the current year.

Insider Buying and Selling at IDEXX Laboratories

In related news, Director Lawrence D. Kingsley sold 2,203 shares of the business's stock in a transaction that occurred on Friday, September 4th. The shares were sold at an average price of $532.08, for a total transaction of $1,172,172.24. Following the completion of the sale, the director directly owned 9,568 shares of the company's stock, valued at $5,090,941.44. The trade was a 18.72% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. 0.79% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on IDXX. Weiss Ratings raised IDEXX Laboratories from a "hold (c)" rating to a "hold (c+)" rating in a report on Thursday, October 8th. UBS Group increased their price objective on shares of IDEXX Laboratories from $620.00 to $670.00 and gave the stock a "neutral" rating in a report on Wednesday, August 5th. Citigroup boosted their target price on shares of IDEXX Laboratories from $650.00 to $670.00 and gave the stock a "neutral" rating in a research note on Wednesday, August 5th. The Goldman Sachs Group began coverage on shares of IDEXX Laboratories in a research report on Friday, October 16th. They set a "buy" rating and a $740.00 target price on the stock. Finally, KeyCorp started coverage on shares of IDEXX Laboratories in a research note on Monday, October 12th. They set a "sector weight" rating on the stock. Seven analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $744.09.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc NASDAQ: IDXX develops and provides diagnostic, information technology, and related products and services for the animal health and water testing markets. The company primarily serves veterinary practices, helping them diagnose and monitor diseases through laboratory tests, in-clinic analyzers, software, and digital practice-management solutions.

IDEXX's companion animal offerings include hematology, chemistry, urinalysis, immunodiagnostics, and imaging-related products, along with reference laboratory services and veterinary software.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.